Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,522

Document Document Title
WO/2021/069570A1
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...  
WO/2021/025973A1
The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.  
WO/2021/023100A1
Disclosed are deoxycholic acid compounds, pharmaceutical compositions thereof and the use thereof in the preparation of drugs for treating liver diseases. The structure of the deoxycholic acid compounds is as shown in formula I, or a pha...  
WO/2021/025974A1
The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.  
WO/2020/264512A1
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/200335A1
The invention provides 3α5β–steroid compounds of general formula I. These compounds are useful in the treatment of epilepsy or comorbidities associated with epilepsy or conditions associated with convulsions, such as seizures associa...  
WO/2020/187965A1
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.  
WO/2020/182228A1
A method of refining sodium taurocholate is disclosed. The method comprises dissolving a crude sodium taurocholate product in an alcohol solvent, adding an ester solvent while hot, filtering after cooling, and drying under reduced pressu...  
WO/2020/172289A1
Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C1...  
WO/2020/168283A1
The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compou...  
WO/2020/146541A3
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/119836A8
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...  
WO/2020/146541A2
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/132504A1
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...  
WO/2020/128514A1
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...  
WO/2020/119836A1
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...  
WO/2020/115371A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2020/118060A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2 a, R2 b, R4 a, R4 b, R6a, R6b, R7a,R7b,R11a, R11b, R12a,R12b, R18, RD, and q are defined herein. L is selected...  
WO/2020/084094A1
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...  
WO/2020/053509A1
The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is n...  
WO/2020/025942A1
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...  
WO/2020/020728A1
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...  
WO/2019/232208A1
Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ca...  
WO/2019/209850A1
Described herein is the chemical structure of neurosteroid derivative compounds, methods of synthesizing the derivatives, and their uses in treating disorders, including those of the central nervous system. These compounds are readily sy...  
WO/2019/191637A1
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.  
WO/2019/176079A1
[Problem] To provide a biodegradable compound that has a structure degraded in cells, a lipid particle comprising the biodegradable compound and a medicinal composition containing the lipid particle. [Solution] According to one embodimen...  
WO/2019/173642A1
The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a po...  
WO/2019/151838A1
Disclosed are a composition for clearing spheroids, a method for clearing spheroids using same, and a kit comprising same. The composition for clearing spheroids can clear the spheroids in a convenient and rapid manner and thus may be us...  
WO/2019/129913A1
The present invention relates to compounds of formula (I) derived from ursodeoxycholic acid, to processes for preparing them and to their use for the treatment of polycystic diseases, in particular autosomal dominant polycystic liver dis...  
WO/2019/129309A1
Provided is a preparation method for a dexamethasone intermediate, relating to the field of active pharmaceutical ingredient synthesis. Compound I in a buffer salt system undergoes a cyanide reaction to synthesize 17α-CN, and said produ...  
WO/2019/129176A1
The present invention provides a sarsasapogenin derivative and a preparation method and application thereof. The derivative has a structure as shown in formula I, and the definition of each substituent is as described in the specificatio...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/119832A1
Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt...  
WO/2019/114525A1
The present application discloses a plurality of novel derivatives of cucurbitacin B and cucurbitacin E, and salts thereof, and also discloses methods for preparing these novel derivatives. These new derivatives and their salts have comm...  
WO/2019/097434A1
The aspects of the present disclosure relates to novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions a...  
WO/2019/081586A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...  
WO/2019/039767A3
The present invention provides a composition for adjusting biological tissue size, and a method for adjusting the size of biological tissue using said composition. A composition for adjusting biological tissue according to the present in...  
WO/2019/039767A2
The present invention provides a composition for adjusting biological tissue size, and a method for adjusting the size of biological tissue using said composition. A composition for adjusting biological tissue according to the present in...  
WO/2018/224736A3
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Rl to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17P-HSD1 and in treatment or preve...  
WO/2018/232502A1
Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from chole...  
WO/2018/237350A1
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug ther...  
WO/2018/223836A1
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the pres...  
WO/2018/224736A2
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2018/213077A1
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are...  
WO/2018/201516A1
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...  
WO/2018/187804A1
The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II) or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR o...  
WO/2018/175582A1
This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate ...  
WO/2018/089373A9
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...  

Matches 1 - 50 out of 2,522